2019
Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease
Afinogenova Y, Ruan J, Yang R, Kleytman N, Pastores G, Lischuk A, Mistry PK. Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease. Molecular Genetics And Metabolism 2019, 128: 62-67. PMID: 31358474, PMCID: PMC6864269, DOI: 10.1016/j.ymgme.2019.07.014.Peer-Reviewed Original ResearchConceptsEnzyme replacement therapyGaucher disease patientsYKL-40 levelsYKL-40Replacement therapyDisease patientsGaucher diseaseBone involvementHealthy controlsProgranulin levelsLong-term enzyme replacement therapyHigh serum YKL-40Cathepsin DSerum YKL-40 levelsGaucher disease mouse modelContribution of fibrosisLower progranulin levelsSerum YKL-40Chemokine ligand 18Disease mouse modelSevere bone involvementCathepsin SPersistent splenomegalyResidual splenomegalyGene array analysis
2017
Neferine, is not inducer but blocker for macroautophagic flux targeting on lysosome malfunction
Xu T, Singh D, Liu J, Li H, Peng S, Rizzolo LJ, Wang SB. Neferine, is not inducer but blocker for macroautophagic flux targeting on lysosome malfunction. Biochemical And Biophysical Research Communications 2017, 495: 1516-1521. PMID: 29197576, DOI: 10.1016/j.bbrc.2017.11.169.Peer-Reviewed Original ResearchConceptsLC3-IIMultiple pharmacological effectsAMPK/mTORNeferine treatmentKnockdown of ATG5Pharmacological effectsCancer cellsNeferineStrong inducerAutophagic fluxCathepsin DPhagocytic cargoLysosome maturationLysosome malfunctionExposureMacroautophagic fluxInducerMaturationAdaptor proteinArrhythmiasBlockersCancerProgranulin acts as a shared chaperone and regulates multiple lysosomal enzymes
Jian J, Hettinghouse A, Liu C. Progranulin acts as a shared chaperone and regulates multiple lysosomal enzymes. Genes & Diseases 2017, 4: 125-126. PMID: 28944282, PMCID: PMC5609500, DOI: 10.1016/j.gendis.2017.05.001.Peer-Reviewed Original ResearchMultiple lysosomal enzymesLysosomal enzymesE domainLysosomal enzyme cathepsin DLysosomal storage diseaseLysosomal enzyme β-glucocerebrosidaseEnzyme cathepsin DC-terminusChaperonesMolecular mechanismsChaperone moleculesEnzyme β-glucocerebrosidaseNeuronal ceroid lipofuscinosisStorage diseaseGaucher diseaseNull miceEnzymeCeroid lipofuscinosisCathepsin DGene variantsMutationsΒ-glucocerebrosidaseRole of progranulinImportant roleProgranulin
2014
Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P. Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. Clinical Cancer Research 2014, 20: 3310-3318. PMID: 24721645, DOI: 10.1158/1078-0432.ccr-13-2906.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBiomarkers, TumorDrug Resistance, NeoplasmFemaleGene Expression ProfilingHumansMaleMelanomaMiddle AgedNeoplasm StagingOligonucleotide Array Sequence AnalysisPrognosisProspective StudiesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateYoung AdultConceptsInterleukin-1 receptor-associated kinase 3Cytotoxic T-lymphocyte-associated antigen 4Federal Drug AdministrationT-lymphocyte-associated antigen 4Multicenter phase II studyPretreatment peripheral blood samplesMulticenter phase III studyThioredoxin reductase 1Four-gene modelCathepsin DCTLA-4 blockadePhase II studyPhase III studyTreatment-naïve patientsSubset of patientsPeripheral blood samplesReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionU.S. Federal Drug AdministrationExpression levelsPrior therapyII studyIII studyClinical predictorsPatient subsets
2013
Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.
Saenger Y, Magidson J, Liaw B, Wassmann K, Barker W, Harcharik S, Fisher D, Oh W, Friedlander P. Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab. Journal Of Clinical Oncology 2013, 31: 9080-9080. DOI: 10.1200/jco.2013.31.15_suppl.9080.Peer-Reviewed Original ResearchPredictive of survivalInterleukin-1 receptor-associated kinase 3CTLA-4Training cohortValidation cohortPredicting SurvivalMulti-center phase II studyAntibody targeting CTLA-4Median time of followT-cell inhibitory moleculesMRNA signatureCTLA-4 blockadeRisk scorePhase II studyPhase III studyMultivariate Cox analysisMinority of patientsPeripheral blood samplesMulti-center phase III studyTime of followStage of diseaseHigh-risk groupLevels of cathepsin DCathepsin DACTLA-4
2007
Altered immunogenicity of isoaspartate containing proteins
Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity 2007, 40: 131-137. PMID: 17453712, DOI: 10.1080/08916930601165180.Peer-Reviewed Original ResearchConceptsPost-translational modificationsIsoaspartyl residuesSuch post-translational modificationsContaining ProteinBiological processesLymphocyte developmentIsoaspartic acidCytochrome cProteinAspartic acidCathepsin DCathepsin digestionPigeon cytochrome cResiduesAntigen processingAltered immunogenicityCellsImmune systemNatural modificationBone marrowToleranceD. AdditionallyEnzymeSpontaneous conversionAcid
1997
Gene Expression of Proteases and Protease Inhibitors in the Human Ciliary Epithelium and ODM-2 Cells
ORTEGO J, ESCRIBANO J, COCA-PRADOS M. Gene Expression of Proteases and Protease Inhibitors in the Human Ciliary Epithelium and ODM-2 Cells. Experimental Eye Research 1997, 65: 289-299. PMID: 9268597, DOI: 10.1006/exer.1997.0333.Peer-Reviewed Original ResearchMeSH KeywordsAgedalpha 1-Antitrypsinalpha-MacroglobulinsBlotting, NorthernBlotting, WesternCarcinogensCathepsin DCathepsin KCathepsinsCell LineCiliary BodyCysteine EndopeptidasesDNA, ComplementaryEndopeptidasesEpithelial CellsGene ExpressionGlycoproteinsHumansMiddle AgedPolymerase Chain ReactionPrecipitin TestsPregnancy ProteinsProtease InhibitorsSerine Proteinase InhibitorsTetradecanoylphorbol AcetateConceptsODM-2 cellsPP5/TFPICiliary epithelial cellsComplementary DNARegulation of transcriptionProteinase inhibitorsEpithelial cellsNon-protein kinase CCathepsin DProtein kinase C activationKinase C activationPattern of expressionCiliary bodyImmunoprecipitation experimentsGene expressionNorthern analysisCultured ciliary epithelial cellsKinase CWestern blot analysisHuman ciliary epitheliumAlpha-phorbol didecanoatePhorbol esterC activationBlot analysisHuman proteinases
1993
Immunohistologic evaluation of invasion-associated proteases in breast carcinoma.
Visscher D, Sarkar F, LoRusso P, Sakr W, Ottosen S, Wykes S, Crissman J. Immunohistologic evaluation of invasion-associated proteases in breast carcinoma. Modern Pathology 1993, 6: 302-6. PMID: 8346178.Peer-Reviewed Original ResearchConceptsBreast carcinomaUrokinase-type plasminogen activatorShort-term recurrence-free survivalCathepsin DNode-positive patientsRecurrence-free survivalProteolytic enzyme expressionHeterogeneous staining patternFree survivalImmunohistologic evaluationMetastatic diseasePositive patientsInflammatory cellsNeoplastic epitheliumExtracellular matrix dissolutionSystematic metastasisClinical aggressivenessMost tumorsTumor componentsMetastatic capacityCryostat sectionsCarcinomaMonoclonal antibodiesStaining patternPlasminogen activator
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply